# Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

> **NCT06171750** · PHASE1 · RECRUITING · sponsor: **Ankyra Therapeutics, Inc** · enrollment: 97 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Cutaneous Tumor
- Subcutaneous Tumor
- Malignant Solid Tumor
- Solid Tumor
- Metastatic Solid Tumor
- Metastasis to Soft Tissue
- Non Small Cell Lung Cancer
- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** tolododekin alfa
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT06171750
- **Lead sponsor:** Ankyra Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-19
- **Primary completion:** 2027-04
- **Final completion:** 2027-06
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06171750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06171750, "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06171750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*